Skip to content

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02198976
Acronym
ABCDE
Enrollment
300
Registered
2014-07-24
Start date
2014-04-30
Completion date
2034-11-30
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett's Esophagus

Brief summary

The purpose of this study is to collect prospective observational data regarding endoscopic management and outcomes of patients with Barrett's oesophagus (BO) with high grade dysplasia and/or intramucosal carcinoma. To observe the natural history of patients with low grade dysplastic and non dysplastic Barrett's oesophagus

Interventions

None listed

Sponsors

Professor Michael Bourke
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Can give informed consent to trial participation * Age greater than 18 * Barrett's oesophagus

Exclusion criteria

* Age less than 18 * Pregnant patients

Design outcomes

Primary

MeasureTime frameDescription
Number of Serious and Non-Serious Adverse EventsDuring the Barretts ExcisionCollect prospective observational data on patients undergoing endoluminal therapy for dysplastic BO to determine * Long term risk of oesophageal adenocarcinoma (OAC) development * Long term efficacy (dysplasia and metaplasia free) in both long and short segment BO * Short and long term safety and complications * Comparison of the safety, long term efficacy, cost and patient tolerability between endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) Document the endoscopic location and characterise morphology of HGD/IMC in short and long segment BO Define the short term and long term causes of morbidity / mortality of patients undergoing ER This will be recorded on a datasheet, de-identified during the procedure.

Secondary

MeasureTime frameDescription
Number of Participants with Serious and Non-Serious Adverse EventsUp to 5 years after procedureEstablish the effect of endoluminal therapies for BO HGD/IMC on oesophageal motility. Document and grade the post EMR oesophageal defect and establish a possible link to subsequent complications (including stricture, bleeding and perforation) and recurrence. Perform cost-utility analyses comparing different treatment approaches for BO HGD/IMC, including EMR, RFA and oesophagectomy. Establish the relationship between Obstructive Sleep Apnea and BO. Understand patient attitudes and perceptions regarding BO, its treatment and its implication. Participants will be approached following their procedure and data recorded on a datasheet, this data will be linked to the initial procedure outcomes.

Countries

Australia

Contacts

Primary ContactMichael Bourke, MBBS
michael@citywestgastro.com.au88905555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026